Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson, Timothy S. Racie, Birgit Bramlage, Akin Akinc, David Butler, Klaus Charisse, Robert Dorkin, Yupeng Fan, Christina Gamba-Vitalo, Philipp Hadwiger, Muthusamy Jayaraman, Matthias John, K. Narayanannair Jayaprakash, Martin Maier, Lubomir Nechev, Kallanthottathil G. Rajeev, Timothy Read, Ingo Röhl & 13 others Jürgen Soutschek, Pamela Tan, Jamie Wong, Gang Wang, Tracy Zimmermann, Antonin De Fougerolles, Hans Peter Vornlocher, Robert Langer, Daniel G. Anderson, Muthiah Manoharan, Victor Koteliansky, Jay D. Horton, Kevin Fitzgerald

Research output: Contribution to journalArticle

435 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of targeting murine, rat, nonhuman primate (NHP), and human PCSK9. For in vivo studies, PCSK9 and control siRNAs were formulated in a lipidoid nanoparticle (LNP). Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50-70%. The reduction in PCSK9 transcript was associated with up to a 60% reduction in plasma cholesterol concentrations. These effects were shown to be mediated by an RNAi mechanism, using 5′-RACE. In transgenic mice expressing human PCSK9, siRNAs silenced the human PCSK9 transcript by >70% and significantly reduced PCSK9 plasma protein levels. In NHP, a single dose of siRNA targeting PCSK9 resulted in a rapid, durable, and reversible lowering of plasma PCSK9, apolipoprotein B, and LDLc, without measurable effects on either HDL cholesterol (HDLc) or triglycerides (TGs). The effects of PCSK9 silencing lasted for 3 weeks after a single bolus i.v. administration. These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

Original languageEnglish (US)
Pages (from-to)11915-11920
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number33
DOIs
StatePublished - Aug 19 2008

Fingerprint

LDL Cholesterol
Primates
Rodentia
Cholesterol
Small Interfering RNA
LDL Receptors
low density lipoprotein inhibitor
Proprotein Convertase 9
RNAi Therapeutics
Liver
Apolipoproteins B
RNA Interference
Hypercholesterolemia
Nanoparticles
HDL Cholesterol
Transgenic Mice
Blood Proteins
Triglycerides
Messenger RNA

Keywords

  • Plasma PCSK9
  • Tissue LDLR levels

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. / Frank-Kamenetsky, Maria; Grefhorst, Aldo; Anderson, Norma N.; Racie, Timothy S.; Bramlage, Birgit; Akinc, Akin; Butler, David; Charisse, Klaus; Dorkin, Robert; Fan, Yupeng; Gamba-Vitalo, Christina; Hadwiger, Philipp; Jayaraman, Muthusamy; John, Matthias; Jayaprakash, K. Narayanannair; Maier, Martin; Nechev, Lubomir; Rajeev, Kallanthottathil G.; Read, Timothy; Röhl, Ingo; Soutschek, Jürgen; Tan, Pamela; Wong, Jamie; Wang, Gang; Zimmermann, Tracy; De Fougerolles, Antonin; Vornlocher, Hans Peter; Langer, Robert; Anderson, Daniel G.; Manoharan, Muthiah; Koteliansky, Victor; Horton, Jay D.; Fitzgerald, Kevin.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 33, 19.08.2008, p. 11915-11920.

Research output: Contribution to journalArticle

Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A, Butler, D, Charisse, K, Dorkin, R, Fan, Y, Gamba-Vitalo, C, Hadwiger, P, Jayaraman, M, John, M, Jayaprakash, KN, Maier, M, Nechev, L, Rajeev, KG, Read, T, Röhl, I, Soutschek, J, Tan, P, Wong, J, Wang, G, Zimmermann, T, De Fougerolles, A, Vornlocher, HP, Langer, R, Anderson, DG, Manoharan, M, Koteliansky, V, Horton, JD & Fitzgerald, K 2008, 'Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 33, pp. 11915-11920. https://doi.org/10.1073/pnas.0805434105
Frank-Kamenetsky, Maria ; Grefhorst, Aldo ; Anderson, Norma N. ; Racie, Timothy S. ; Bramlage, Birgit ; Akinc, Akin ; Butler, David ; Charisse, Klaus ; Dorkin, Robert ; Fan, Yupeng ; Gamba-Vitalo, Christina ; Hadwiger, Philipp ; Jayaraman, Muthusamy ; John, Matthias ; Jayaprakash, K. Narayanannair ; Maier, Martin ; Nechev, Lubomir ; Rajeev, Kallanthottathil G. ; Read, Timothy ; Röhl, Ingo ; Soutschek, Jürgen ; Tan, Pamela ; Wong, Jamie ; Wang, Gang ; Zimmermann, Tracy ; De Fougerolles, Antonin ; Vornlocher, Hans Peter ; Langer, Robert ; Anderson, Daniel G. ; Manoharan, Muthiah ; Koteliansky, Victor ; Horton, Jay D. ; Fitzgerald, Kevin. / Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 33. pp. 11915-11920.
@article{bf362caf52ba4b0db9e69dffaa940197,
title = "Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates",
abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of targeting murine, rat, nonhuman primate (NHP), and human PCSK9. For in vivo studies, PCSK9 and control siRNAs were formulated in a lipidoid nanoparticle (LNP). Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50-70{\%}. The reduction in PCSK9 transcript was associated with up to a 60{\%} reduction in plasma cholesterol concentrations. These effects were shown to be mediated by an RNAi mechanism, using 5′-RACE. In transgenic mice expressing human PCSK9, siRNAs silenced the human PCSK9 transcript by >70{\%} and significantly reduced PCSK9 plasma protein levels. In NHP, a single dose of siRNA targeting PCSK9 resulted in a rapid, durable, and reversible lowering of plasma PCSK9, apolipoprotein B, and LDLc, without measurable effects on either HDL cholesterol (HDLc) or triglycerides (TGs). The effects of PCSK9 silencing lasted for 3 weeks after a single bolus i.v. administration. These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.",
keywords = "Plasma PCSK9, Tissue LDLR levels",
author = "Maria Frank-Kamenetsky and Aldo Grefhorst and Anderson, {Norma N.} and Racie, {Timothy S.} and Birgit Bramlage and Akin Akinc and David Butler and Klaus Charisse and Robert Dorkin and Yupeng Fan and Christina Gamba-Vitalo and Philipp Hadwiger and Muthusamy Jayaraman and Matthias John and Jayaprakash, {K. Narayanannair} and Martin Maier and Lubomir Nechev and Rajeev, {Kallanthottathil G.} and Timothy Read and Ingo R{\"o}hl and J{\"u}rgen Soutschek and Pamela Tan and Jamie Wong and Gang Wang and Tracy Zimmermann and {De Fougerolles}, Antonin and Vornlocher, {Hans Peter} and Robert Langer and Anderson, {Daniel G.} and Muthiah Manoharan and Victor Koteliansky and Horton, {Jay D.} and Kevin Fitzgerald",
year = "2008",
month = "8",
day = "19",
doi = "10.1073/pnas.0805434105",
language = "English (US)",
volume = "105",
pages = "11915--11920",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "33",

}

TY - JOUR

T1 - Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

AU - Frank-Kamenetsky, Maria

AU - Grefhorst, Aldo

AU - Anderson, Norma N.

AU - Racie, Timothy S.

AU - Bramlage, Birgit

AU - Akinc, Akin

AU - Butler, David

AU - Charisse, Klaus

AU - Dorkin, Robert

AU - Fan, Yupeng

AU - Gamba-Vitalo, Christina

AU - Hadwiger, Philipp

AU - Jayaraman, Muthusamy

AU - John, Matthias

AU - Jayaprakash, K. Narayanannair

AU - Maier, Martin

AU - Nechev, Lubomir

AU - Rajeev, Kallanthottathil G.

AU - Read, Timothy

AU - Röhl, Ingo

AU - Soutschek, Jürgen

AU - Tan, Pamela

AU - Wong, Jamie

AU - Wang, Gang

AU - Zimmermann, Tracy

AU - De Fougerolles, Antonin

AU - Vornlocher, Hans Peter

AU - Langer, Robert

AU - Anderson, Daniel G.

AU - Manoharan, Muthiah

AU - Koteliansky, Victor

AU - Horton, Jay D.

AU - Fitzgerald, Kevin

PY - 2008/8/19

Y1 - 2008/8/19

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of targeting murine, rat, nonhuman primate (NHP), and human PCSK9. For in vivo studies, PCSK9 and control siRNAs were formulated in a lipidoid nanoparticle (LNP). Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50-70%. The reduction in PCSK9 transcript was associated with up to a 60% reduction in plasma cholesterol concentrations. These effects were shown to be mediated by an RNAi mechanism, using 5′-RACE. In transgenic mice expressing human PCSK9, siRNAs silenced the human PCSK9 transcript by >70% and significantly reduced PCSK9 plasma protein levels. In NHP, a single dose of siRNA targeting PCSK9 resulted in a rapid, durable, and reversible lowering of plasma PCSK9, apolipoprotein B, and LDLc, without measurable effects on either HDL cholesterol (HDLc) or triglycerides (TGs). The effects of PCSK9 silencing lasted for 3 weeks after a single bolus i.v. administration. These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma LDLc. Here, we have developed active, cross-species, small interfering RNAs (siRNAs) capable of targeting murine, rat, nonhuman primate (NHP), and human PCSK9. For in vivo studies, PCSK9 and control siRNAs were formulated in a lipidoid nanoparticle (LNP). Liver-specific siRNA silencing of PCSK9 in mice and rats reduced PCSK9 mRNA levels by 50-70%. The reduction in PCSK9 transcript was associated with up to a 60% reduction in plasma cholesterol concentrations. These effects were shown to be mediated by an RNAi mechanism, using 5′-RACE. In transgenic mice expressing human PCSK9, siRNAs silenced the human PCSK9 transcript by >70% and significantly reduced PCSK9 plasma protein levels. In NHP, a single dose of siRNA targeting PCSK9 resulted in a rapid, durable, and reversible lowering of plasma PCSK9, apolipoprotein B, and LDLc, without measurable effects on either HDL cholesterol (HDLc) or triglycerides (TGs). The effects of PCSK9 silencing lasted for 3 weeks after a single bolus i.v. administration. These results validate PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

KW - Plasma PCSK9

KW - Tissue LDLR levels

UR - http://www.scopus.com/inward/record.url?scp=50149101511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149101511&partnerID=8YFLogxK

U2 - 10.1073/pnas.0805434105

DO - 10.1073/pnas.0805434105

M3 - Article

VL - 105

SP - 11915

EP - 11920

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 33

ER -